You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameApixaban
Accession NumberDB06605  (DB07828)
TypeSmall Molecule
GroupsApproved
DescriptionApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.
Structure
Thumb
Synonyms
apixabán
apixabanum
External Identifiers
  • BMS 562247-01
  • BMS-562247
  • BMS-562247-01
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet2.5 mgOralBristol Myers Squibb Canada2012-02-01Not applicableCanada
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mg/1OralCardinal Health2012-12-28Not applicableUs
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet5.0 mgOralBristol Myers Squibb Canada2012-12-21Not applicableCanada
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mg/1OralA S Medication Solutions2012-12-28Not applicableUs
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mg/1OralE.R. Squibb & Sons, L.L.C.2012-12-28Not applicableUs
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mg/1OralA S Medication Solutions2012-12-28Not applicableUs
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mg/1OralE.R. Squibb & Sons, L.L.C.2012-12-28Not applicableUs
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3Z9Y7UWC1J
CAS number503612-47-3
WeightAverage: 459.4971
Monoisotopic: 459.190654313
Chemical FormulaC25H25N5O4
InChI KeyQNZCBYKSOIHPEH-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
IUPAC Name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide
SMILES
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Pharmacology
IndicationApixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
Structured Indications
PharmacodynamicsApixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban. The Rotachrom® Heparin chromogenic assay is not recommended for assessing the anticoagulant effect of apixaban.
Mechanism of actionApixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Coagulation factor XProteinyes
inhibitor
HumanP00742 details
Related Articles
AbsorptionApixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%. For oral administration, absorption is not affected by the presence of food, and it takes about 3-4 hours to achieve maximum plasma concentrations. For large oral doses equal or greater than 25 mg, absorption is dissolution limited and bioavailability is decreased. Most of the absorption occurs in the distal small intestine and the ascending colon.
Volume of distribution

The steady state volume of distribution is 21 L.

Protein bindingApixaban is about 87% plasma protein bound.
Metabolism

Apixaban mainly undergoes o-demethylation and hydroxylation to metabolites. The major site of biotransformation is at the 3-oxopiperidinyl moiety. The main enzyme responsible for metabolism is CYP3A4/5 while CYP1A2, 2C8, 2C9, 2C19, and 2J2 are minor metabolic enzymes. There are no active metabolites and unchanged apixaban is the primary circulating entity.

Route of elimination25% of the administered dose is eliminated in the feces and urine. For elimination in the feces, it is excreted by the intestine and bile to the feces.
Half lifeIf administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.
Clearance

About 27% of total apixaban is renally cleared.

ToxicityMajor bleeding events.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Apixaban.Approved, Investigational
AbciximabApixaban may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Apixaban can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Apixaban.Approved
AcenocoumarolApixaban may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Apixaban can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Apixaban.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Apixaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Apixaban.Approved
AfatinibThe serum concentration of Apixaban can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Apixaban can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Apixaban can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Apixaban can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Apixaban can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Apixaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Apixaban.Approved, Illicit, Investigational
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Apixaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Apixaban.Approved
AltrenogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Apixaban.Investigational
AmantadineThe serum concentration of Apixaban can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Apixaban.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Apixaban.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Apixaban can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Apixaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Apixaban.Approved
AmiodaroneThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Apixaban.Approved
AmlodipineThe serum concentration of Apixaban can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Apixaban can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Apixaban can be increased when it is combined with Amsacrine.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Apixaban.Approved
AncrodApixaban may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Apixaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Apixaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Apixaban.Approved
Antithrombin III humanApixaban may increase the anticoagulant activities of Antithrombin III human.Approved
ApremilastApremilast may increase the anticoagulant activities of Apixaban.Approved, Investigational
AprepitantThe serum concentration of Apixaban can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Apixaban can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinApixaban may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanApixaban may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Apixaban can be decreased when combined with Armodafinil.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Apixaban.Investigational
AstemizoleThe serum concentration of Apixaban can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Apixaban can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Apixaban can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Apixaban.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Apixaban.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Apixaban.Approved
AzithromycinThe serum concentration of Apixaban can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Apixaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Apixaban.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Apixaban.Approved, Investigational
BecaplerminApixaban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Apixaban.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Apixaban.Withdrawn
BenzocaineThe serum concentration of Apixaban can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Apixaban can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Apixaban.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Apixaban.Investigational
BexaroteneThe serum concentration of Apixaban can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Apixaban can be increased when it is combined with Biperiden.Approved
BivalirudinApixaban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Apixaban can be decreased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Apixaban can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Apixaban can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Apixaban can be increased when it is combined with Bosutinib.Approved
BromfenacBromfenac may increase the anticoagulant activities of Apixaban.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Apixaban.Investigational
BuprenorphineThe serum concentration of Apixaban can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Apixaban can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Apixaban.Investigational
CabazitaxelThe serum concentration of Apixaban can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Apixaban.Approved
CaffeineThe serum concentration of Apixaban can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Apixaban can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Apixaban can be increased when it is combined with Candesartan.Approved
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Apixaban.Approved
CapecitabineThe metabolism of Apixaban can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Apixaban can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Apixaban can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Apixaban.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Apixaban can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Apixaban can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Apixaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
CeritinibThe serum concentration of Apixaban can be increased when it is combined with Ceritinib.Approved
CertoparinApixaban may increase the anticoagulant activities of Certoparin.Approved
ChloramphenicolThe metabolism of Apixaban can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Apixaban can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Apixaban.Withdrawn
ChlorpromazineThe serum concentration of Apixaban can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Apixaban can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Apixaban can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Apixaban can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Apixaban can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Apixaban can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Apixaban can be increased when it is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Apixaban.Approved
CimetidineThe serum concentration of Apixaban can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Apixaban can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Apixaban.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Apixaban can be increased when it is combined with Citalopram.Approved
Citric AcidApixaban may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.Approved
ClemastineThe serum concentration of Apixaban can be increased when it is combined with Clemastine.Approved
ClofazimineThe serum concentration of Apixaban can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Apixaban.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Apixaban.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Apixaban.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Apixaban can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Apixaban can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Apixaban can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Apixaban can be increased when it is combined with Colforsin.Experimental
CollagenaseThe risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase.Approved
ConivaptanThe serum concentration of Apixaban can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Apixaban.Approved
CrizotinibThe serum concentration of Apixaban can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Apixaban.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Apixaban.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Apixaban can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Apixaban.Investigational
Dabigatran etexilateApixaban may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Apixaban can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Apixaban can be increased when it is combined with Dactinomycin.Approved
DalteparinApixaban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidApixaban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe serum concentration of Apixaban can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Apixaban.Approved, Investigational
DaunorubicinThe serum concentration of Apixaban can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Apixaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Apixaban.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Apixaban is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Apixaban.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Apixaban.Approved
DesirudinApixaban may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Apixaban can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Apixaban.Investigational
DesogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of Apixaban can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranApixaban may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Apixaban may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Apixaban may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Apixaban may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Apixaban can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Apixaban can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolApixaban may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Apixaban.Approved
DienogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Apixaban.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Apixaban.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Apixaban.Approved
DihydroergotamineThe serum concentration of Apixaban can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Apixaban can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Apixaban.Approved
DitazoleDitazole may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Apixaban.Approved
DoxazosinThe serum concentration of Apixaban can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Apixaban.Approved
DoxorubicinThe serum concentration of Apixaban can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Apixaban can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Apixaban can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Apixaban can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Apixaban.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Apixaban.Investigational
DydrogesteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Apixaban.Approved
E6201E6201 may increase the anticoagulant activities of Apixaban.Investigational
EbselenEbselen may increase the anticoagulant activities of Apixaban.Investigational
Edetic AcidApixaban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanApixaban may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Apixaban can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Apixaban can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Apixaban can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Apixaban can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Apixaban.Approved, Investigational
EnoxaparinApixaban may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Apixaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Apixaban.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Apixaban.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Apixaban.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Apixaban.Approved
ErythromycinThe serum concentration of Apixaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Apixaban can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Apixaban.Investigational
EsomeprazoleThe metabolism of Apixaban can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Apixaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Apixaban.Approved
EstriolEstriol may decrease the anticoagulant activities of Apixaban.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Apixaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Apixaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Apixaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Apixaban.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Apixaban.Approved
Ethyl biscoumacetateApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Apixaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Apixaban.Approved
EtonogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Apixaban can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Apixaban.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Apixaban.Approved
exisulindexisulind may increase the anticoagulant activities of Apixaban.Investigational
FelodipineThe serum concentration of Apixaban can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Apixaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Apixaban.Approved
FentanylThe serum concentration of Apixaban can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Apixaban can be increased when it is combined with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Apixaban.Approved
FidaxomicinThe serum concentration of Apixaban can be increased when it is combined with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
FloxuridineThe metabolism of Apixaban can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Apixaban can be increased when it is combined with Fluconazole.Approved
FluindioneApixaban may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Apixaban.Vet Approved
FluorouracilThe metabolism of Apixaban can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Apixaban can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Apixaban can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Apixaban can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Apixaban can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Apixaban.Approved, Investigational
FluvastatinThe metabolism of Apixaban can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Apixaban can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxApixaban may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumApixaban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Apixaban can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Apixaban can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Apixaban can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Apixaban can be increased when it is combined with Fusidic Acid.Approved
GabexateApixaban may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Apixaban can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Apixaban can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Apixaban can be decreased when combined with Gemfibrozil.Approved
GenisteinGenistein may decrease the anticoagulant activities of Apixaban.Investigational
GestodeneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestrinone.Approved
GlyburideThe serum concentration of Apixaban can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Apixaban can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Apixaban can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Apixaban can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Apixaban can be increased when it is combined with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Apixaban.Approved
HeparinApixaban may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Apixaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Apixaban.Investigational
HirulogApixaban may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Apixaban.Investigational
HydrocortisoneThe serum concentration of Apixaban can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Apixaban.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Apixaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Apixaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Apixaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Apixaban.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Apixaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Apixaban can be increased when it is combined with Idelalisib.Approved
idraparinuxApixaban may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Apixaban.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Apixaban.Approved, Investigational
ImatinibThe serum concentration of Apixaban can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Apixaban.Approved
IndinavirThe serum concentration of Apixaban can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Apixaban.Investigational
IndomethacinThe serum concentration of Apixaban can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Apixaban.Withdrawn
IrbesartanThe metabolism of Apixaban can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Apixaban can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Apixaban can be decreased when combined with Isoniazid.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Apixaban.Withdrawn
IsradipineThe serum concentration of Apixaban can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Apixaban can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Apixaban can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Apixaban can be increased when it is combined with Ivermectin.Approved, Vet Approved
Kct 0809Kct 0809 may increase the anticoagulant activities of Apixaban.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Apixaban.Experimental
KetamineThe serum concentration of Apixaban can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Apixaban.Investigational
KetoconazoleThe serum concentration of Apixaban can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Apixaban.Approved
LansoprazoleThe serum concentration of Apixaban can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Apixaban can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Apixaban can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinApixaban may increase the anticoagulant activities of Lepirudin.Approved
LevofloxacinThe serum concentration of Apixaban can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevothyroxineThe serum concentration of Apixaban can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Apixaban can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Apixaban.Approved
LiothyronineThe serum concentration of Apixaban can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Apixaban can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Apixaban can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Apixaban.Investigational
LomitapideThe serum concentration of Apixaban can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Apixaban can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Apixaban can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Apixaban.Approved
LosartanThe serum concentration of Apixaban can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Apixaban.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Apixaban.Approved
LuliconazoleThe serum concentration of Apixaban can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Apixaban can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
LynestrenolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Apixaban.Approved
MaprotilineThe serum concentration of Apixaban can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Apixaban.Approved
MebendazoleThe serum concentration of Apixaban can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Apixaban.Approved
MefloquineThe serum concentration of Apixaban can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
MeprobamateThe serum concentration of Apixaban can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Apixaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Apixaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Apixaban.Withdrawn
MethadoneThe serum concentration of Apixaban can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Apixaban.Experimental
MetoprololThe serum concentration of Apixaban can be increased when it is combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Apixaban can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Apixaban can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Apixaban can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Apixaban.Approved, Illicit
MifepristoneThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Apixaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Apixaban.Approved
MitomycinThe serum concentration of Apixaban can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Apixaban can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Apixaban can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Apixaban.Investigational
MoclobemideThe metabolism of Apixaban can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Apixaban can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Apixaban can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Apixaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Apixaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Apixaban.Approved
NadroparinApixaban may increase the anticoagulant activities of Nadroparin.Approved
NafamostatApixaban may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Apixaban can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may increase the anticoagulant activities of Apixaban.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Apixaban.Investigational
NaltrexoneThe serum concentration of Apixaban can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban.Approved, Vet Approved
NaringeninThe serum concentration of Apixaban can be increased when it is combined with Naringenin.Experimental
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Apixaban.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Apixaban.Approved, Withdrawn
NelfinavirThe serum concentration of Apixaban can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Apixaban can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Apixaban.Approved
NetupitantThe serum concentration of Apixaban can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Apixaban can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Apixaban can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Apixaban can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Apixaban.Approved
NilotinibThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apixaban.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Apixaban is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Apixaban can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Apixaban can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Apixaban can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apixaban.Investigational
NomegestrolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Norethisterone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Apixaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.Approved
OlaparibThe serum concentration of Apixaban can be increased when it is combined with Olaparib.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Apixaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Apixaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Apixaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Apixaban.Approved
OmeprazoleThe serum concentration of Apixaban can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Apixaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Apixaban.Vet Approved
OsimertinibThe serum concentration of Apixaban can be increased when it is combined with Osimertinib.Approved
OtamixabanApixaban may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Apixaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Apixaban.Withdrawn
P-NitrophenolThe serum concentration of Apixaban can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Apixaban can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Apixaban can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Apixaban can be increased when it is combined with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Apixaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Apixaban.Approved
ParoxetineThe serum concentration of Apixaban can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateApixaban may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Apixaban.Approved, Investigational
PerindoprilThe serum concentration of Apixaban can be increased when it is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Apixaban is combined with Pethidine.Approved
PhenindioneApixaban may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonApixaban may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
PhenytoinThe serum concentration of Apixaban can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Apixaban.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Apixaban.Approved
PioglitazoneThe metabolism of Apixaban can be decreased when combined with Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Apixaban.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Apixaban.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Apixaban.Investigational
Platelet Activating FactorThe serum concentration of Apixaban can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Apixaban.Approved
PonatinibThe serum concentration of Apixaban can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Apixaban can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Apixaban.Approved
PravastatinThe serum concentration of Apixaban can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Apixaban can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Apixaban can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Apixaban can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Apixaban can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Apixaban.Investigational
PromethazineThe serum concentration of Apixaban can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Apixaban.Approved
PropafenoneThe serum concentration of Apixaban can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Apixaban can be increased when it is combined with Propranolol.Approved, Investigational
Protein CApixaban may increase the anticoagulant activities of Protein C.Approved
Protein S humanApixaban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeApixaban may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.Approved
PTC299PTC299 may increase the anticoagulant activities of Apixaban.Investigational
PyrimethamineThe metabolism of Apixaban can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Apixaban can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Apixaban can be increased when it is combined with Quinacrine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Apixaban.Approved
QuinidineThe serum concentration of Apixaban can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Apixaban can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Apixaban can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Apixaban.Investigational
RanitidineThe serum concentration of Apixaban can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Apixaban can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Apixaban can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Apixaban can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Apixaban can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Apixaban.Approved
ReviparinApixaban may increase the anticoagulant activities of Reviparin.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Apixaban.Approved
RifabutinThe serum concentration of Apixaban can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Apixaban can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Apixaban can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Apixaban can be increased when it is combined with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Apixaban.Approved
RitonavirThe serum concentration of Apixaban can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanApixaban may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Apixaban.Investigational, Withdrawn
RolapitantThe serum concentration of Apixaban can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Apixaban can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Apixaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Apixaban.Approved
S EquolS Equol may decrease the anticoagulant activities of Apixaban.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Apixaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Apixaban.Approved
SaquinavirThe serum concentration of Apixaban can be increased when it is combined with Saquinavir.Approved, Investigational
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Apixaban.Investigational
ScopolamineThe serum concentration of Apixaban can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Apixaban can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Apixaban.Investigational
SelegilineThe serum concentration of Apixaban can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Apixaban.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Apixaban.Approved, Investigational
SertralineThe serum concentration of Apixaban can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Apixaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Apixaban.Approved, Investigational
SiltuximabThe serum concentration of Apixaban can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Apixaban.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Apixaban.Approved
SirolimusThe serum concentration of Apixaban can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Apixaban can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Apixaban can be increased when it is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Apixaban.Investigational
St. John's WortThe serum concentration of Apixaban can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Apixaban can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Apixaban can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Apixaban.Approved
StreptozocinThe serum concentration of Apixaban can be decreased when it is combined with Streptozocin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Apixaban.Approved
SulfadiazineThe metabolism of Apixaban can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Apixaban can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Apixaban.Approved
SulfinpyrazoneThe serum concentration of Apixaban can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Apixaban can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Apixaban.Approved
SulodexideApixaban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Apixaban can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Apixaban can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Apixaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Apixaban.Approved
TacrineThe serum concentration of Apixaban can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Apixaban.Approved, Investigational
TacrolimusThe serum concentration of Apixaban can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Apixaban can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Apixaban can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Apixaban can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Apixaban can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Apixaban can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Apixaban.Approved
TenofovirThe metabolism of Apixaban can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the anticoagulant activities of Apixaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Apixaban.Vet Approved
TerazosinThe serum concentration of Apixaban can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Apixaban can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Apixaban can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Apixaban.Investigational
TestosteroneThe serum concentration of Apixaban can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Apixaban can be decreased when combined with Theophylline.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Apixaban.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Apixaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Apixaban.Approved
TicagrelorThe serum concentration of Apixaban can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Apixaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Apixaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Apixaban.Approved
TipranavirThe serum concentration of Apixaban can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Apixaban.Approved
TocilizumabThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Apixaban can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Apixaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Apixaban.Approved
TolvaptanThe serum concentration of Apixaban can be increased when it is combined with Tolvaptan.Approved
TopiramateThe metabolism of Apixaban can be decreased when combined with Topiramate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Apixaban.Approved, Investigational
TranylcypromineThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.Approved
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Apixaban.Approved
TrazodoneThe serum concentration of Apixaban can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Apixaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Apixaban.Approved
TrifluoperazineThe serum concentration of Apixaban can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Apixaban can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Apixaban.Approved
TrimethoprimThe serum concentration of Apixaban can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Apixaban.Approved
TroleandomycinThe serum concentration of Apixaban can be increased when it is combined with Troleandomycin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Apixaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Apixaban.Approved, Investigational
ValsartanThe metabolism of Apixaban can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Apixaban can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Apixaban can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Apixaban can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Apixaban can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Apixaban can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Apixaban can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Apixaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Apixaban.Approved
VoriconazoleThe serum concentration of Apixaban can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinApixaban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranApixaban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Apixaban may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Apixaban can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Apixaban.Approved
ZeranolZeranol may decrease the anticoagulant activities of Apixaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Apixaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Apixaban can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Apixaban can be increased when it is combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Apixaban.Withdrawn
Food Interactions
  • Alfalfa, Anise, Bilberry may increase the adverse effects of apixaban.
  • Grapefruit juice may increase apixaban serum concentration.
  • St. John's wort will likely decrease apixaban serum concentration. Avoid combination if possible.
References
Synthesis ReferenceNot Available
General References
  1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. [PubMed:21870978 ]
  2. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974 ]
External Links
ATC CodesB01AF02
AHFS Codes
  • 20:12.04.14
PDB EntriesNot Available
FDA labelDownload (655 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9329
Caco-2 permeable-0.5308
P-glycoprotein substrateSubstrate0.6144
P-glycoprotein inhibitor IInhibitor0.6804
P-glycoprotein inhibitor IIInhibitor0.594
Renal organic cation transporterNon-inhibitor0.5628
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.811
CYP450 3A4 substrateSubstrate0.764
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6447
Ames testNon AMES toxic0.5062
CarcinogenicityNon-carcinogens0.8796
BiodegradationNot ready biodegradable0.9965
Rat acute toxicity2.3038 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8351
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral2.5 mg
TabletOral5.0 mg
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral5 mg
Tablet, film coatedOral5 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2349330 No2009-09-292019-12-17Canada
CA2461202 No2011-07-122022-09-17Canada
US6413980 No1999-12-222019-12-22Us
US6967208 No2003-02-032023-02-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityAqueous solubility: 40-50 μg/ml in 0.9% saline solutionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0679 mg/mLALOGPS
logP2.22ALOGPS
logP1.83ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)13.12ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.76 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity126.9 m3·mol-1ChemAxon
Polarizability49.62 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylpyrazole
  • Methoxyaniline
  • Pyridinecarboxamide
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Piperidinone
  • Delta-lactam
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrazole
  • Azole
  • Tertiary amine
  • Primary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Spyropoulos AC: Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007 Apr;16(4):431-40. [PubMed:17371192 ]
  2. Harenberg J, Wehling M: Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. [PubMed:18393142 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ: In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. [PubMed:19940026 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:40 / Updated on December 07, 2016 02:40